1-toifa qandli diabeti bor bemorlarda melatoninning uyqu sifati va glikemik nazoratga ta’siri

The objective of this study was to evaluate the effect of melatonin on sleep quality and glycemic control in patients with type 1 diabetes mellitus (T1DM). A prospective, randomized, double-blind, placebo-controlled study was conducted involving 80 patients with T1DM aged 18-35 years. Patients were randomized into two groups: the main group (2 mg melatonin) and the control group (placebo). The duration of therapy was 16 weeks. The evaluation included polysomnography, HbA1c, continuous glucose monitoring, and glycemic variability parameters. In the melatonin group, a statistically significant improvement in sleep architecture was observed: sleep efficiency increased from 78.2±8.4% to 86.7±6.2% (p<0.001), sleep latency decreased from 34.6±12.8 to 18.3±7.4 minutes (p<0.001), and the proportion of slow-wave sleep increased from 16.8±4.2% to 22.1±5.6% (p<0.01). A reduction in HbA1c from 8.4±1.2% to 7.8±0.9% (p<0.01), an increase in time in the target glucose range from 58.3±14.7% to 68.9±12.4% (p<0.001), and a decrease in the glucose coefficient of variation from 42.6±8.9% to 36.2±7.1% (p<0.01) were also observed. No significant changes were identified in the placebo group. No adverse effects were reported. Melatonin effectively improves sleep quality and glycemic control in patients with T1DM, which may be attributable to the restoration of circadian rhythms and improved insulin sensitivity.

Hali tarjima qilinmagan